TechMARK movers: Microsoft deal boosts ARM

23rd Jul 2010 15:09

Shares in chip designer ARM have jumped on the back of a new licensing deal with Microsoft. The architecture licence will extend the collaborative relationship that has been ongoing since 1997. AstraZeneca is sliding on worries over whether or not its new heart drug Brilinta will be approved by the FDA panel when it meets on 28 July. A lack of benefit was shown in trials of Brilinta in North America but the FDA may decide that this is a regional anomaly because results in other areas have been positive.in North America, patients also taking aspirin did not get a positive effect. There may not eve be a definitive answer after the meeting. The FDA may ask for more trials. AstraZeneca will report second quarter figures on 29 July. FTSE TechMARK - RisersTorotrak (TRK) 25.00p +13.64%ARM Holdings (ARM) 353.80p +11.79%Intec Telecom Systems (ITL) 55.00p +10.00%Filtronic (FTC) 33.50p +8.06%BATM Advanced (BVC) 25.25p +7.45%Phytopharm (PYM) 8.13p +4.90%NXT (NTX) 9.50p +4.05%Ricardo Group (RCDO) 247.00p +3.78%Vislink (VLK) 18.75p +2.74%Kofax (KFX) 248.50p +2.69%FTSE TechMARK - FallersElectronic Data Processing (EDP) 45.00p -3.33%Antisoma (ASM) 6.00p -2.44%Innovation Group (TIG) 11.50p -2.13%AstraZeneca (AZN) 3,152.00p -2.20%Triad Group (TRD) 24.00p -2.08%Autonomy Corporation (AU.) 1,618.00p -1.88%Anite Group (AIE) 40.25p -1.83%BTG (BGC) 205.50p -1.44%Oxford Biomedica (OXB) 9.76p -1.21%Wolfson Microelectronics (WLF) 168.00p -1.18%